KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Idexx Laboratories (IDXX) over the last 17 years, with Q3 2025 value amounting to $402.3 million.

  • Idexx Laboratories' Cash from Operations rose 8281.62% to $402.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 1867.78%. This contributed to the annual value of $929.0 million for FY2024, which is 248.11% up from last year.
  • As of Q3 2025, Idexx Laboratories' Cash from Operations stood at $402.3 million, which was up 8281.62% from $185.7 million recorded in Q2 2025.
  • In the past 5 years, Idexx Laboratories' Cash from Operations registered a high of $402.3 million during Q3 2025, and its lowest value of $65.8 million during Q2 2022.
  • In the last 5 years, Idexx Laboratories' Cash from Operations had a median value of $200.3 million in 2023 and averaged $208.4 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 34642.1% in 2021, then tumbled by 7185.36% in 2022.
  • Over the past 5 years, Idexx Laboratories' Cash from Operations (Quarter) stood at $210.0 million in 2021, then decreased by 17.4% to $173.4 million in 2022, then surged by 44.07% to $249.9 million in 2023, then grew by 4.87% to $262.0 million in 2024, then surged by 53.55% to $402.3 million in 2025.
  • Its Cash from Operations was $402.3 million in Q3 2025, compared to $185.7 million in Q2 2025 and $238.0 million in Q1 2025.